Our portfolio of life science and healthcare companies - Start Codon

Don’t invest unless you’re prepared to lose all your money invested. Investments in our companies are high-risk investments. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Please take 2 mins to learn more by clicking this link and viewing our summary of key risks.

Our portfolio

Our portfolio of exciting life science and healthcare companies

Adora

Adora has developed an AI-driven digital health platform that empowers women and transforms the menopause experience through conversational chat bots, exceptional content and a female-focused brand.
ArkVax

LSHTM spin-out leveraging glycoengineering to develop next-gen vaccines for animals and humans.
Cardiac Tech

Cardiac Tech is a med-tech company that is changing the safety paradigm in post-cardiac surgical recovery.
Coding Bio

Coding.bio is building best-in-class chimeric antigen receptors (CARs) using an AI-first approach combined with its proprietary screening platform to rapidly develop and validate new CARs directed against both existing and novel antigen targets.
CoSyne Therapeutics

CoSyne Therapeutics is a computational drug discovery company based in London and Cambridge. They are bringing biology and chemistry to hyper scale compute by combing human tissue with polymathic AI. They are on a mission to push the boundaries of technology to improve the lives of patients. Their first goal is to treat brain cancer.
Drishti Discoveries

Drishti Discoveries develops transformative treatments through its proprietary RNA-mediated gene silencing platform.
Enhanc3D Genomics

A functional genomics spin-out of the Babraham Institute (Cambridge, UK) whose platform technology links non-coding sequence variants to their target genes in order to identify novel therapeutic targets.
Ephyra

A National University of Singapore spin-out pioneering the development of circRNA-based molecular sponges to sequester disease-causing molecules.
Erebagen

Erebagen is a spin out of the University of Warwick and has developed a novel chemical synthetic biology platform that unlocks the full industrial potential of microbes to develop treatments for diseases.
Indegra Therapeutics

An integrin inhibitor discovery platform, designed to unlock new treatments for multiple diseases.
NK:IO

NK:IO is a natural killer cell therapy company that has developed a novel and proprietary method for the differentiation, expansion and activation of NK cells without exhaustion.
Octiocor

A spin-out company of the University of Cambridge aiming to prevent heart attacks via high-res coronary artery imaging.
Proxximos

{Proxximos have developed a revolutionary digital solution for healthcare infection prevention and control
RevoNA

University of Portsmouth spin-out disrupting RNA drug discovery.
Semarion

Semarion is a University of Cambridge spin-out that is revolutionising cell-based assays for drug discovery and life sciences through its proprietary SemaCyte® microcarrier platform, which leverages novel materials physics for assay miniaturisation, multiplexing, and automation.
Spirea

Spirea is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells, resulting in greater efficacy, tolerability and the ability to treat more cancer patients.
Spliceor

Spliceor is an RNA gene therapy company that uses trans-splicing to drive suicide gene expression in specific cell types for selective depletion (e.g. killing cancerous, immune or senescent cells with a pro-drug).
StemBond Technologies

University of Cambridge spin-out revolutionising cell culture for regenerative medicine.
Tagomics

Tagomics is has developed a comprehensive and disruptive epigenetic biomarker discovery platform to advance non-invasive healthcare.
Verinnogen

Verinnogen have developed an innovative device that enhances tumour volume estimation in cancer research.
Zygosity

Zygosity's proprietary platform enables significantly enhanced gene editing precision and efficacy by eliminating mosaicism, thereby reducing the time and costs of experiments by orders of magnitude and enabling broader adoption of in vivo and ex vivo CRISPR therapeutic applications.

Do you want to join us, work with us or be involved with our portfolio?

Get in contact Get in contact